Medtronic launches VenaSeal; MIT opens Hong Kong research center;

@FierceMedDev: ICYMI: Dx Digest: Illumina launches $250M share repurchase program; Foundation Medicine stumbles with Q3 earnings miss. Article | Follow @FierceMedDev

@VarunSaxena2: The 11th commandment: Thou shall mention Botox in every article about Allergan. (Perhaps the deal is a ploy to increase its sales?!) | Follow @VarunSaxena2

@EmilyWFierce: Lilly, Merck join Valeant in DOJ spotlight with new inquiries on pricing. FiercePharma story | Follow @EmilyWFierce

> The FDA has expanded the label for the iFuse Implant System from SI-Bone for fusion for certain disorders of the sacroiliac joint to include that it improved pain, patient function and quality of life at 12 months. More

> Medtronic ($MDT) has launched its VenaSeal closure system for varicose veins in the U.S. after a PMA approval by the FDA in February. It's the first non-tumescent, non-thermal, non-sclerosant procedure approved for the treatment of symptomatic venous reflux available in the country, according to the company. More

> Radiopharmaceuticals company Advanced Accelerator Applications is aiming for a $75 million IPO this week. More

> MIT has announced a new research center in Hong Kong that may be used for medical device prototyping, among other activities. Story

Biotech News

@FierceBiotech: FT: Amgen in the hunt for a $10B biotech buyout. Report | Follow @FierceBiotech

@JohnCFierce: So does anybody else think the FDA 's BTD program has run amuck? Teva's SD-809 is a BTD? Really? | Follow @JohnCFierce

@DamianFierce: Worried about a sophomore slump with this new $VRX album. More | Follow @DamianFierce

> Agios slips on mixed solid tumor data for its Celgene-partnered cancer drug. News

> Collegium's pain drug wins a 'tentative' FDA approval with Purdue blocking the way. Article

Pharma News

@FiercePharma: Academic vets make strides in ongoing fight against deadly pig viruses. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Novo makes sure Denmark gets some of the action as it starts massive build up. Story | Follow @EricPFierce

@CarlyHFierce: Valeant board, Ackman back CEO Pearson as shares continue downward dive. More | Follow @CarlyHFierce

> Chicago makes second run at Allergan, J&J, Purdue and others with painkiller lawsuit. News

> Amgen scores PCSK9 exclusive in pay-for-performance deal with Harvard Pilgrim. Story

Animal Health News

> Schein outpaces Q3 earnings estimates but dampens full-year forecast. Item

> Academic vets make strides in ongoing fight against deadly pig viruses. More

> Sanofi explores 'strategic options' for Merial in bid to cut costs. Report

> Aratana misses Q3 sales targets, refocuses priorities on pain and appetite drugs. Story

> Trupanion coasts in Q3 with veterinary hospital push delivering sales. Article

Biotech IT News

> Transcriptic adds CRISPR gene editing to robotic lab. Story

> Cognizant lands IT deal with 100,000 Genomes Project. More

> Ex-trailblazer Knome accepts buyout bid from tiny Tute. Report

> SEC pursues trader over 'phony tweets' that sank Sarepta's stock. Story

> Flush with $90M in VC cash, Twist and Ginkgo strike massive synthetic DNA deal. Article

Pharma Marketing News

> Real-life insomnia stories at core of new Merck-backed awareness campaign. Article

> Are Takeda's 900 Contrave reps worth it? Maybe not, analyst says. More

> Lilly, Merck and Valeant feel sting of DOJ drug pricing probe. Report

> Want to win on pricing? Take a closer look at the numbers. Story

> Allergan pumps up its sales rep tally amid Viberzi launch, aesthetics push. Article

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.